Antihyperglycemic activity evaluation and chemical profiling of edible pericarps of phaseolus vulgaris L RSPHO 1.1 // GP // Prof. Dr. Amany El-Brairy // A.L. MahaMousa Mahmoud (2018 - 2019)
- Giza : MSA, 2019.
- 61 p.
- PHARMACY DISTINGUISHED PROJECTS 2019 .
Pharmacy - Pharmacology
Diabetes is considered a serious metabolic disorder characterized by hyperglycemia due to absolute insulin deficiency or complete destruction of pancreatic beta cells (Type 1 diabetes) and beta cells receptors resistance (Type 2 DM). Diabetes complications are peripheral vascular diseases, coronary vascular diseases and sexual dysfunction. Conventional drugs cause adverse effects and have high cost. Nowadays, herbal drugs are used due to their natural origin and affordable cost. The study aims to evaluate the antidiabetic activity of phaseolusvulgare L pericarps. Diabetes was induced through a single IP injection of 55 mg /kg of STZ and rats was randomly divided into 6 groups each contain 6 rats Group 1: Normal control (received saline), Group 2: Diabetic control, Group 3: Diabetic group received standard drug glibenclamide (600 ug /kg P.O.) , Group 4: Diabetic group received non polar fraction of phaseolus vulgaris extract (200 mg P.O.), Group 5: Diabetic group received MSCs ( 106 cell /rat IP ) and Group 6 : Diabetic group received both NPF phaseolus vulgaris and MSCs. Phaseolus vulgaris significantly decreases glucose level , MDA, cholesterol and TGs (P<0.005) and significantly increases insulin level , Nitric oxide (NO) and HDL (P<0.005).While stem cells group significantly decreases glucose level, MDA (P<0.005) and slight decrease in cholesterol and no significant decrease in TGs .Combined group shows low glucose & MDA level and increase in insulin , nitric oxide and HDL level . The study showed that NPF phaseolus vulgaris (200mg /kg), stem cells and combined have antidiabetic activity